Distributor inventory | Tablet

Type 2 diabetes mellitus (adult) when blood sugar is not adequately controlled with diet/exercise and single or dual therapy; helps control post‑meal and fasting blood glucose

Metformin reduces glucose production in the liver and improves insulin sensitivity. Glimepiride stimulates the pancreas to release insulin. Voglibose delays carbohydrate absorption in the gut by inhibiting alpha‑glucosidase enzymes, reducing post‑meal glucose spikes.

Oral tablet. Take exactly as prescribed, usually once daily with food (typically with the first main meal); swallow whole if prolonged‑release—do not crush/chew. Follow diet and exercise advice and monitor blood glucose regularly.

Hypoglycaemia, nausea, diarrhoea, abdominal pain, flatulence, bloating, headache, dizziness, weight gain, taste changes

Risk of hypoglycaemia (higher with missed meals, excess exercise, alcohol, elderly); lactic acidosis risk with metformin (avoid in severe kidney disease, severe dehydration, sepsis, hypoxia). Check renal function before and during therapy; use caution in liver disease and heart failure. Stop metformin temporarily before iodinated contrast/surgery as advised by doctor. Seek urgent care for symptoms of low sugar (sweating, tremor, confusion) or lactic acidosis (deep/rapid breathing, severe weakness, abdominal pain).

Alcohol (increases hypoglycaemia and lactic acidosis risk), iodinated contrast media, insulin/other antidiabetics (additive hypoglycaemia), beta‑blockers (may mask hypoglycaemia), corticosteroids and thiazide diuretics (raise glucose), ACE inhibitors (may increase hypoglycaemia), fluoroquinolones (glucose disturbances), cimetidine (may increase metformin levels)

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister and out of reach of children.

Amaryl M V 2/0.3 Tablet, Gluconorm GMV 2/0.3 Tablet, Gemer V 2/0.3 Tablet, Zoryl MV 2/0.3 Tablet, Glimisave MV 2/0.3 Tablet